Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced a strategic collaboration with TARA Mind, working alongside Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The partnership aims to expand mental health awareness within the veteran community while advancing the development of HLP003, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration.
The collaboration leverages the networks of TARA Mind and VETS to enhance veteran engagement in clinical research. This initiative aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, underscoring the importance of addressing mental health challenges among veterans. Helus Pharma is advancing its HLP003 program and broader pipeline of novel serotonergic agonists designed to address unmet mental health needs.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs) that aim to promote neuroplasticity by activating serotonin pathways. The company’s lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.
The full press release is available at https://ibn.fm/o9dCH. For the latest news on HELP, visit the company’s newsroom at https://ibn.fm/HELP.
